- Home
- PUBM vs ALDX Comparison
PUBM vs ALDX Comparison
Compare PUBM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- ALDX
- Stock Information
- Founded
- PUBM 2006
- ALDX 2004
- Country
- PUBM United States
- ALDX United States
- Employees
- PUBM N/A
- ALDX N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PUBM Technology
- ALDX Health Care
- Exchange
- PUBM Nasdaq
- ALDX Nasdaq
- Market Cap
- PUBM 382.7M
- ALDX 342.3M
- IPO Year
- PUBM 2020
- ALDX 2014
- Fundamental
- Price
- PUBM $8.63
- ALDX $4.90
- Analyst Decision
- PUBM Buy
- ALDX Strong Buy
- Analyst Count
- PUBM 11
- ALDX 2
- Target Price
- PUBM $18.05
- ALDX $9.50
- AVG Volume (30 Days)
- PUBM 597.1K
- ALDX 781.4K
- Earning Date
- PUBM 11-11-2025
- ALDX 11-06-2025
- Dividend Yield
- PUBM N/A
- ALDX N/A
- EPS Growth
- PUBM N/A
- ALDX N/A
- EPS
- PUBM N/A
- ALDX N/A
- Revenue
- PUBM $292,208,000.00
- ALDX N/A
- Revenue This Year
- PUBM N/A
- ALDX N/A
- Revenue Next Year
- PUBM $1.70
- ALDX $63.48
- P/E Ratio
- PUBM N/A
- ALDX N/A
- Revenue Growth
- PUBM 3.53
- ALDX N/A
- 52 Week Low
- PUBM $7.01
- ALDX $1.14
- 52 Week High
- PUBM $17.74
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PUBM 45.79
- ALDX 33.59
- Support Level
- PUBM $8.13
- ALDX $5.48
- Resistance Level
- PUBM $8.54
- ALDX $5.88
- Average True Range (ATR)
- PUBM 0.33
- ALDX 0.30
- MACD
- PUBM 0.13
- ALDX -0.13
- Stochastic Oscillator
- PUBM 70.41
- ALDX 1.54
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.